IMAGES IN DERMATOLOGY

Azithromycin for the Treatment of Ciclosporin-Induced Gingival Hyperplasia

Utilidad de la azitromicina en la hiperplasia gingival inducida por ciclosporina

J.M. Martín, a,b,* E. Mateo, c E. Jordá a,b

a Servicio de Dermatología, Hospital Clínico Universitario, Valencia, Spain
b Departamento de Medicina, Universidad de Valencia, Valencia, Spain
c Servicio de Medicina Interna, Hospital Universitario Dr. Peset, Valencia, Spain

Figure 1

Our patient was a 33-year-old woman who had received allogenic stem cell transplant for hepatosplenic T-cell lymphoma. She was administered ciclosporin, 150 mg/d, as prophylaxis for graft-versus-host disease and developed progressive gingival hyperplasia, most evident 2 months after starting treatment (Fig. 1A). She was then administered azithromycin, 500 mg daily for 3 days, which produced a considerable improvement at 3 weeks (Fig. 1B).

Gingival hyperplasia is a known complication of treatment with ciclosporin. It occurs in approximately 30% of cases, but its pathogenesis remains unknown. The mechanism of action of azithromycin is not fully understood, but it has been suggested that the drug may have a triple action in the resolution of certain periodontal diseases, due to its antimicrobial and anti-inflammatory activity and its capacity to persist at low concentrations in the macrophages and fibroblasts of the periodontal tissues, even when administered in short-term regimens of 3 to 5 days.

In more prolonged treatments, the interaction that occurs between the 2 drugs would require ciclosporin levels to be monitored and great care to be taken in patients with alterations of cardiac repolarization.

Please cite this article as: Martín JM, Mateo E, Jordá E. Utilidad de la azitromicina en la hiperplasia gingival inducida por ciclosporina. Actas Dermosifiliogr. 2016;107:780.

* Corresponding author.
E-mail addresses: Martin.josemaria@gmail.com, jmmart@eresmas.com (J.M. Martín).

1578-2190/© 2016 Elsevier España, S.L.U. and AEDV. All rights reserved.